Rebrace Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.50 M
- Revenue Growth 114.94%
- Profit Growth 135.12%
- Ebitda 195.23%
- Net Worth 194.59%
- Total Assets 100.66%
About Rebrace Pharmaceuticals
Rebrace Pharmaceuticals Private Limited (RPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 18 August 2020 (Four years and five months 29 days old ). Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹7.50 M.
Rohit Swarnakar, Neena Rasaily, Kabita Medhi, and One other member serve as directors at the Company.
Company Details
-
Location
24 Parganas, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909WB2020PTC238994
-
Company No.
238994
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Aug 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
What products or services does Rebrace Pharmaceuticals Private Limited offer?
Rebrace Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Herbal Piles Medicine.
Who are the key members and board of directors at Rebrace Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Swarnakar
|
Director | 18-Aug-2020 | Current |
|
Neena Rasaily
|
Director | 18-Aug-2020 | Current |
|
Kabita Medhi
|
Director | 20-Jan-2021 | Current |
|
Sourami Saha
|
Additional Director | 16-May-2023 | Current |
Financial Performance of Rebrace Pharmaceuticals.
Rebrace Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 114.94% increase. The company also saw a substantial improvement in profitability, with a 135.12% increase in profit. The company's net worth Soared by an impressive increase of 194.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rebrace Pharmaceuticals?
Unlock access to Rebrace Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹7.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Dec 2023 | Others | ₹7.50 M | Open |
How Many Employees Work at Rebrace Pharmaceuticals?
Rebrace Pharmaceuticals has a workforce of 34 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rebrace Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rebrace Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
